Edward M. Md Kaye Sells 10,382 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Stoke Therapeutics Stock Down 2.2 %

Shares of NASDAQ STOK opened at $8.15 on Friday. Stoke Therapeutics, Inc. has a twelve month low of $5.93 and a twelve month high of $17.58. The company has a 50 day moving average of $9.47 and a 200 day moving average of $11.45. The firm has a market cap of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. As a group, equities analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in STOK. KLP Kapitalforvaltning AS bought a new position in shares of Stoke Therapeutics in the 4th quarter worth approximately $63,000. Teacher Retirement System of Texas bought a new position in Stoke Therapeutics in the fourth quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Stoke Therapeutics during the 4th quarter worth $124,000. Tower Research Capital LLC TRC grew its position in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after acquiring an additional 4,918 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics in the 4th quarter worth $133,000.

Analyst Ratings Changes

A number of analysts recently commented on STOK shares. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and a consensus price target of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.